Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHARMACOGENETICS OF ANTIDEPRESSANTS - CLINICAL ASPECTS
Autore:
BERTILSSON L; DAHL ML; TYBRING G;
Indirizzi:
HUDDINGE HOSP S-14186 HUDDINGE SWEDEN HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL S-14186 HUDDINGE SWEDEN
Titolo Testata:
Acta psychiatrica Scandinavica
, volume: 96, anno: 1997, supplemento:, 391
pagine: 14 - 21
SICI:
0001-690X(1997)96:<14:POA-CA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-LIVER-MICROSOMES; POLYMORPHIC DEBRISOQUINE HYDROXYLATION; SEROTONIN REUPTAKE INHIBITORS; OXIDATION POLYMORPHISM; TRICYCLIC ANTIDEPRESSANTS; AMITRIPTYLINE METABOLISM; SWEDISH POPULATION; POOR METABOLIZERS; DRUG-METABOLISM; PLASMA-LEVEL;
Keywords:
PHARMACOGENETICS; ANTIDEPRESSANTS; P450;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
62
Recensione:
Indirizzi per estratti:
Citazione:
L. Bertilsson et al., "PHARMACOGENETICS OF ANTIDEPRESSANTS - CLINICAL ASPECTS", Acta psychiatrica Scandinavica, 96, 1997, pp. 14-21

Abstract

Plasma concentrations and response to antidepressants vary considerably between patients treated with similar dosages. Most antidepressantsand also antipsychotics are metabolized by the polymorphic debrisoquine/sparteine hydroxylase. i.e., cytochrome P450 (CYP)2D6. About 7% of Caucasians are poor metabolizers (PM), and such patients might developadverse drug reactions when treated with recommended doses of for example, tricyclic antidepressants. In contrast, ultrarapid metabolizers with multiple CYP2D6 genes might require high doses of such drugs for optimal therapy, The mean CYP2D6 activity is lower in Oriental than inCaucasian populations, because of a frequent mutation causing decreased enzyme activity, Drugs metabolized by the same enzyme may interact with each other, For example. the potent CYP2D6 inhibitor fluoxetine increases the plasma concentrations of tricyclic antidepressants. Another enzyme catalyzing the metabolism of antidepressants is the polymorphic S-mephenytoin hydroxylase, CYP2C19, which catalyses the metabolismof for example, citalopram. clomipramine and moclobemide. Various probe drugs may be used for phenotyping CYP2D6 (debrisoquine, dextromethorphan and sparteine) and CYP2C19 (mephenytoin and omeprazole). Allele-specific polymerase chain reaction (PCR)-based methods are now available for genotyping using leukocyte DNA. A major advantage of genotypingcompared with phenotyping is that the former may be performed in blood samples from patients irrespective of treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 01:17:22